scispace - formally typeset
Open AccessJournal ArticleDOI

The Pathophysiology and Treatment of Glaucoma: A Review

Reads0
Chats0
TLDR
Primary care physicians can play an important role in the diagnosis of glaucoma by referring patients with positive family history or with suspicious optic nerve head findings for complete ophthalmologic examination and can improve treatment outcomes by reinforcing the importance of medication adherence and persistence.
Abstract
Importance Glaucoma is a worldwide leading cause of irreversible vision loss. Because it may be asymptomatic until a relatively late stage, diagnosis is frequently delayed. A general understanding of the disease pathophysiology, diagnosis, and treatment may assist primary care physicians in referring high-risk patients for comprehensive ophthalmologic examination and in more actively participating in the care of patients affected by this condition. Objective To describe current evidence regarding the pathophysiology and treatment of open-angle glaucoma and angle-closure glaucoma. Evidence Review A literature search was conducted using MEDLINE, the Cochrane Library, and manuscript references for studies published in English between January 2000 and September 2013 on the topics open-angle glaucoma and angle-closure glaucoma. From the 4334 abstracts screened, 210 articles were selected that contained information on pathophysiology and treatment with relevance to primary care physicians. Findings The glaucomas are a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and resulting changes in the optic nerve head. Loss of ganglion cells is related to the level of intraocular pressure, but other factors may also play a role. Reduction of intraocular pressure is the only proven method to treat the disease. Although treatment is usually initiated with ocular hypotensive drops, laser trabeculoplasty and surgery may also be used to slow disease progression. Conclusions and Relevance Primary care physicians can play an important role in the diagnosis of glaucoma by referring patients with positive family history or with suspicious optic nerve head findings for complete ophthalmologic examination. They can improve treatment outcomes by reinforcing the importance of medication adherence and persistence and by recognizing adverse reactions from glaucoma medications and surgeries.

read more

Citations
More filters
Journal ArticleDOI

Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.

TL;DR: In this phase 3 study, LBN 0.024% qpm demonstrated significantly greater IOP lowering than timolol 0.5% BID throughout the day over 3 months of treatment, and was effective and safe in adults with OAG or OHT.
Journal ArticleDOI

Chitosan coated PLGA nanoparticles amplify the ocular hypotensive effect of forskolin: Statistical design, characterization and in vivo studies.

TL;DR: CS-PLGA-NP's could be successfully formulated and are an excellent vehicle for FK in ocular delivery while increased effectiveness after single instillation in reducing the intraocular pressure was observed.
Journal ArticleDOI

Injectable hydrogels for ophthalmic applications.

TL;DR: The properties of injectable hydrogels are introduced and their versatile application in the treatment of ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic retinopathy, glaucoma, and intraocular cancers is summarized.
Journal ArticleDOI

Risk factors for rapid glaucoma disease progression

TL;DR: Cardiovascular disease is an important risk factor for rapid glaucoma disease progression irrespective of IOP control and was more likely to have pseudoexfoliation, disc haemorrhages, ocular medication changes, and IOP-lowering surgery.
Journal ArticleDOI

Deep Learning Approaches Predict Glaucomatous Visual Field Damage from OCT Optic Nerve Head En Face Images and Retinal Nerve Fiber Layer Thickness Maps.

TL;DR: Deep learning models had high accuracy in identifying eyes with GFVD and predicting the severity of functional loss from SD OCT images, and outperformed standard RNFL thickness measurements in predicting all quantitative VF metrics.
References
More filters
Journal ArticleDOI

The number of people with glaucoma worldwide in 2010 and 2020

TL;DR: Glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians, and it will be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020, and of these, 74% will have OAG.
Journal ArticleDOI

The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma

TL;DR: Topical ocular hypotensive medication was effective in delaying or preventing the onset of POAG in individuals with elevated IOP, and clinicians should consider initiating treatment for individuals with ocular hypertension who are at moderate or high risk for developing POAG.
Journal ArticleDOI

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

TL;DR: The first adequately powered randomized trial with an untreated control arm to evaluate the effects of IOP reduction in patients with open-angle glaucoma who have elevated and normal IOP showed considerable beneficial effects of treatment that significantly delayed progression.
Journal ArticleDOI

The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration

TL;DR: In both analyses low intraocular pressure is associated with reduced progression of visual field defect, supporting evidence from earlier studies of a protective role for low intracular pressure in visual field deterioration.
Related Papers (5)